This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

B. Riley Securities analyst Mayank Mamtani initiated coverage on Cue Biopharma Inc (NASDAQ: CUE) with a Buy rating and set a price target of $83, while the stock closed at $37.84 on Thursday. This initiation is part of a broader trend where analysts are adjusting their ratings on various companies, including First Tracks Biotherapeutics and Boyd Group Services, with price targets significantly above their current closing prices.